FDA approves Auvelity for Alzheimer’s disease-related agitation

The U.S. Food and Drug Administration has approved the expanded use of Axsome Therapeutics’ Auvelity (dextromethorphan hydrobromide and bupropion hydrochloride) extended-release tablets to treat adults with agitation associated with dementia due to Alzheimer’s disease.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup